| Followers | 843 |
| Posts | 122886 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Monday, March 13, 2023 11:11:29 AM
PFE acquires SGEN for $229/sh cash—a 42% premium to SGEN’s “unaffected” share price on 2/24/23:
https://s28.q4cdn.com/781576035/files/doc_news/2023/03/Pfizer-to-Acquire-Seagen-03-13-23.pdf
The nominal deal value is $43B including assumption of debt. The deal is expected to close in late 2023 or 2024 due to a lengthy review by antitrust regulators.
PFE-SGEN CC slides:
https://s28.q4cdn.com/781576035/files/doc_presentation/2023/03/Pfizer-Seagen-Analyst-Call-Slides-Final-03-13-23-_Update.pdf
2-page infographic:
https://s28.q4cdn.com/781576035/files/doc_events/2023/Mar/13/Infographic.pdf
https://s28.q4cdn.com/781576035/files/doc_news/2023/03/Pfizer-to-Acquire-Seagen-03-13-23.pdf
The nominal deal value is $43B including assumption of debt. The deal is expected to close in late 2023 or 2024 due to a lengthy review by antitrust regulators.
PFE-SGEN CC slides:
https://s28.q4cdn.com/781576035/files/doc_presentation/2023/03/Pfizer-Seagen-Analyst-Call-Slides-Final-03-13-23-_Update.pdf
2-page infographic:
https://s28.q4cdn.com/781576035/files/doc_events/2023/Mar/13/Infographic.pdf
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent PFE News
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company • Business Wire • 04/24/2026 10:59:00 AM
- Pfizer Declares Second-Quarter 2026 Dividend • Business Wire • 04/22/2026 08:45:00 PM
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 • Business Wire • 04/21/2026 03:51:00 PM
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility • PR Newswire (US) • 04/20/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 05:16:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:31:02 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 05:10:35 PM
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders • Business Wire • 04/09/2026 02:00:00 PM
- Telix Strengthens Board with Additional Director Appointments • GlobeNewswire Inc. • 04/08/2026 10:44:20 PM
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities • GlobeNewswire Inc. • 04/07/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 09:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:22:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:21:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:20:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:19:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:19:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 12:18:19 AM
- Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts • Business Wire • 03/24/2026 02:00:00 PM
- Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial • Business Wire • 03/23/2026 10:45:00 AM
- Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC • Business Wire • 03/20/2026 08:30:00 PM
- Pfizer’s TALZENNA combination shows progress against prostate cancer • IH Market News • 03/19/2026 02:44:13 PM
- TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer • Business Wire • 03/19/2026 10:45:00 AM
- Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer • Business Wire • 03/17/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:45:46 PM
